Legend Biotech Corporation (LEGN) reported five-year follow-up data from CARTITUDE-2 Cohort A evaluating CARVYKTI® in patients with relapsed/refractory multiple myeloma after one to three prior lines of therapy. The data were presented at the 2026 International Myeloma Society Annual Meeting.
With a median follow-up of 60.7 months, 10 of 20 patients (50%) remained alive and progression-free without maintenance therapy at least five years after a single infusion. Median progression-free survival was 60.5 months; 69.2% of patients were alive at five years, and median overall survival had not been reached.
Legend said the longer-follow-up safety profile was consistent with CARVYKTI’s known safety profile, with no new CAR T-cell-related neurotoxicity reported. Since the prior analysis, which had approximately 30 months of median follow-up, one patient developed a new hematologic malignancy (acute myeloid leukemia), and two deaths occurred due to progressive disease and new cancer. CARTITUDE-2 is an ongoing Phase 2 multicohort study.
Legend Biotech Corporation held its 2026 annual general meeting on September 24, 2026, with approximately 330,199,682 ordinary shares, including those underlying ADSs, represented in person or by proxy. That was approximately 84.9% of the 388,976,826 ordinary shares issued and outstanding as of August 17, 2026. Shareholders voted on audited financial statements, ratification of Ernst & Young LLP as fiscal 2026 independent auditor, four Class III director elections, amendment and restatement of the 2020 Restricted Shares Plan, and authorization of directors and officers.
The plan amendment received 279,130,008 votes for, 20,732,988 against and 30,336,686 abstentions. The election tally for Robin Meng was 273,381,862 for and 56,768,390 against; Dr. Corazon D. Sanders received 326,472,036 votes for, Dr. Li Mao 328,120,942, and Dr. Peter Salovey 328,187,592.
Legend Biotech Corp Chief Financial Officer Carlos E. Santos received a grant of 19,676 Ordinary Shares on September 21, 2026. That same day, Santos sold 5,430 Ordinary Shares at a weighted average price of $9.14 per share to satisfy withholding tax obligations upon vesting of restricted share units; sale prices ranged from $8.905 to $9.325 per share. No Rule 10b5-1 plan is reported.
Legend Biotech Corp (LEGN) is the issuer of American Depositary Shares that a shareholder, Carlos E. Santos, has filed to sell under Rule 144. The notice covers a proposed sale of 2,715 American Depositary Shares through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of $50,854.12 as of September 22, 2026.
The shares were acquired from the issuer on September 18, 2026 via restricted stock vesting as compensation. The filing states that the sale includes an amount necessary to cover a tax obligation resulting from the settlement of the vested equity award distribution.
Legend Biotech Corp (LEGN) is the issuer of American depositary shares that Ying Huang, a former officer and director, has notified an intention to sell under Rule 144. The notice covers 69,812 American depositary shares, expected to be sold on or about September 22, 2026, in connection with a stock option exercise for cash.
The filing lists Fidelity Brokerage Services LLC as the broker and indicates that, over the prior three months, Ying Huang sold 2,783 American depositary shares on June 26, 2026, for $79,016.88. The planned sale covered by the notice has an indicated aggregate market value of $1,302,109.37.
Legend Biotech Corp (symbol: LEGN) is the issuer of record for a Form 4 filing submitted to the SEC. Zhang Ingrid reported acquisition or exercise transactions in this Form 4 filing.
Legend Biotech Corp (LEGN) reported that Chief Executive Officer Ingrid Zhang received an equity award of 1,131,860 restricted share units (RSUs) on September 15, 2026. Each RSU is a contingent right to one ordinary share, vesting in three equal installments on September 15, 2027, 2028, and 2029, subject to continued service.
All 1,131,860 ordinary shares underlying these RSUs are reported as directly owned after the transaction, and the award was granted at a reported price of $0.00 per share. The company notes that its ordinary shares may be represented by ADSs, with each ADS equal to two ordinary shares.
Legend Biotech Corp (LEGN) reported that Ingrid Zhang, Chief Executive Officer, has filed an initial statement of beneficial ownership as an officer of the company. The report lists no equity transactions or holdings and notes an attached Exhibit 24 – Power of Attorney.
Legend Biotech Corp (LEGN) appointed Ingrid Zhang as Chief Executive Officer and principal executive officer effective September 15, 2026, succeeding interim CEO Alan Bash, who returns to his role as President, CARVYKTI. Zhang brings extensive global commercial and leadership experience from senior roles at Novartis, AstraZeneca, Pfizer, and McKinsey.
Under her employment agreement, Zhang receives a $950,000 annual base salary, a discretionary annual cash bonus targeted at 90% of base salary, a one-time signing bonus of $150,000, and an initial restricted share unit award with a grant date fair market value target anticipated to be at least $10 million. Beginning in fiscal 2027, she may be eligible for additional annual RSU awards also targeted at least $10 million, subject to performance and Board or Compensation Committee determinations. The agreement includes clawback of the signing bonus if she departs under specified conditions within 24 months, and severance protections for certain terminations, with enhanced benefits if a qualifying termination occurs within three months before or 18 months after a Change in Control.
Legend Biotech Corporation (LEGN) reports an updated clinical pipeline focused on cell therapies across oncology and autoimmune diseases. The update highlights CARVYKTI, a BCMA-directed autologous therapy developed in collaboration with Janssen, which is listed under NDA status with multiple front-line newly diagnosed multiple myeloma trials (CARTITUDE-5, -6 and -10) in patient follow-up or enrolling. Additional autologous programs include LB1908 for relapsed/refractory gastric and pancreatic cancers and LB2102 for second-line and later small cell lung cancer and large cell neuroendocrine carcinoma, each having met primary endpoints and in patient follow-up. The pipeline also details early-stage autologous, allogeneic and in vivo candidates such as LB2401–LB2406, LB2501, LB2503 and LB2505 for multiple myeloma, B-cell non-Hodgkin lymphoma and autoimmune indications, with several investigator-initiated trials in China and multiple U.S. INDs cleared by the FDA.
Legend Biotech Corp (LEGN) reported that Interim CEO Alan Bash received a grant of 4,908 restricted share units (RSUs) on August 14, 2026. These RSUs convert into ordinary shares on settlement, increasing his direct holdings to 35,142 ordinary shares. The RSUs vest in three equal annual installments on July 27, 2027, 2028, and 2029, subject to continued service. Each ordinary share may also be represented by American Depositary Shares, with one ADS equal to two ordinary shares.